For the quarter ending 2026-03-31, APRE has $47,612,387 in assets. $46,466,202 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 46,466,202 | 14,599,347 | 13,718,052 | 16,532,199 |
| Prepaid expenses and other current assets | 779,238 | 961,899 | 225,936 | 395,011 |
| Total current assets | 47,245,440 | 15,561,246 | 13,943,988 | 16,927,210 |
| Property and equipment, net | 54,379 | 59,807 | 65,236 | 70,665 |
| Restricted cash | 41,406 | 41,186 | 40,930 | 40,673 |
| Other noncurrent assets | 271,162 | 271,162 | 271,162 | 271,162 |
| Total assets | 47,612,387 | 15,933,401 | 14,321,316 | 17,309,710 |
| Accounts payable | 2,940,756 | 713,668 | 641,322 | 1,195,838 |
| Accrued expenses | 2,355,890 | 2,050,690 | 2,039,785 | 1,971,830 |
| Total current liabilities | 5,296,646 | 2,764,358 | 2,681,107 | 3,167,668 |
| Series a convertible preferred stock, 0.001 par value, 40,000,000 shares authorized 31,194 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 727,361 | 727,361 | 727,361 | 727,361 |
| Common stock, 0.001 par value, 400,000,000 shares authorized, 11,982,776 and 8,192,538 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 11,983 | 8,192 | 5,979 | 5,752 |
| Additional paid-in capital | 389,631,454 | 356,709,645 | 352,722,214 | 352,250,747 |
| Subscription receivable | 499,999 | - | - | - |
| Accumulated other comprehensive loss | -10,625,700 | -10,634,714 | -10,629,534 | -10,628,417 |
| Accumulated deficit | -336,929,358 | -333,641,441 | -331,185,811 | -328,213,401 |
| Total stockholders' equity | 41,588,380 | 12,441,682 | 10,912,848 | 13,414,681 |
| Total liabilities and stockholders' equity | 47,612,387 | 15,933,401 | 14,321,316 | 17,309,710 |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)